KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Profit After Tax (2018 - 2025)

Esperion Therapeutics' Profit After Tax history spans 8 years, with the latest figure at $61.8 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 390.04% year-over-year to $61.8 million; the TTM value through Dec 2025 reached -$22.7 million, up 56.17%, while the annual FY2025 figure was -$22.7 million, 56.17% up from the prior year.
  • Profit After Tax reached $61.8 million in Q4 2025 per ESPR's latest filing, up from -$31.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $61.8 million in Q4 2025 to a low of -$90.9 million in Q1 2021.
  • Average Profit After Tax over 5 years is -$39.3 million, with a median of -$52.5 million recorded in 2022.
  • The largest YoY upside for Profit After Tax was 390.04% in 2025 against a maximum downside of 166.3% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$65.1 million in 2021, then grew by 14.79% to -$55.5 million in 2022, then fell by 1.54% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then skyrocketed by 390.04% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Profit After Tax are $61.8 million (Q4 2025), -$31.3 million (Q3 2025), and -$12.7 million (Q2 2025).